Why the Alcidion (ASX:ALC) share price is falling again today

The Alcidion Group Ltd (ASX: ALC) share price has continued its negative run this week and is again backtracking today. We take a closer look into why.

| More on:
white arrow dropping down representing the 10 most shorted shares on the ASX

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Alcidion Group Ltd (ASX: ALC) share price has continued its negative run this week and is again backtracking today. This comes despite the company announcing the completion of its Share Purchase Plan (SSP).

In mid-afternoon trade, the healthcare technology company's shares are down 1.35% to 37 cents.

Why is the Alcidion share price on a downhill trend?

A possible catalyst for the fall of Alcidion shares is that investors are bracing for an impending share dilution.

According to Alcidion's release, the company advised it has successfully completed its SSP following 'very strong support' from shareholders. Over 1,900 applications were received, totalling roughly $30 million. This represents a huge level of investment when compared to the company's target of $2.5 million.

As a result, the board has decided to increase its SPP offer size to $3 million and scale back applications.

With the revised amount, roughly 9.37 million ordinary shares will be issued at a price of 32 cents apiece.

Most applicants will be allotted the minimum basic entitlement of 3,125 SPP shares (worth $1,000). Any remaining SSP shares will be issued on a pro-rata basis on the size of the applicant's shareholding at the record date.

Investors who sold their parcel of shares between the record date and SSP closing date or held less than 1,471 shares will not receive any shares.

Alcidion expects the new shares to be issued and available for trading from next Tuesday.

The capital raising follows the successful institutional placement that was announced on 15 April 2021.

Together, the combined funds for both the placement and SSP will give Alcidion a cash injection of $18.4 million.

Comments from the CEO

Alcidion CEO, Kate Quirke commented on the result of the SSP:

The Company would like to thank all shareholders who participated in the Share Purchase Plan and the Placement for their continued support. We acknowledge that shareholders who subscribed may be disappointed by the scale back. Ultimately, balancing the strong SPP participation with the foreseeable capital needs of the business is in the best interests of all shareholders.

Alcidion share price review

Although Alcidion shares might be modestly lower today, for this week alone, shareholders have recorded a loss of almost 10%. However, when looking at the bigger picture, in year-to-date performance, the Alcidion share price has doubled.

The company has a market capitalisation of approximately $384 million, with more than 1 billion shares on issue.

Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Alcidion Group Ltd. The Motley Fool Australia has recommended Alcidion Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »